Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faricimab vs aflibercept in macular edema secondary to BRVO (Japan phase III)
jRCT2031200455Phase 3Completed
- Sponsor
- Chugai Pharmaceutical Co., Ltd.
- Start
- Apr 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 3, randomised, double-blind trial of faricimab in branch retinal vein occlusion (BRVO) (2 arms), sponsored by Chugai Pharmaceutical Co., Ltd. Primary endpoint: Change from baseline in best-corrected visual acuity (BCVA) at Week 24. Started Apr 2021; status: completed.
02
Drugs
faricimab
03
Conditions
branch retinal vein occlusion (BRVO)
Beyond the preview
Go deeper on jRCT2031200455.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031200455.